{"entity":{"id":"nct05421663","kind":"trial","name":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","aka":[],"tldr":"A phase 1/2 trial of JNJ-90014496 in non-hodgkin lymphoma, run by Janssen Research & Development, LLC, active and no longer recruiting.","summary":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma is a phase 1/2 interventional study registered as NCT05421663 by Janssen Research & Development, LLC, with 166 participants enrolled, started 2022-08-12 and due to reach its primary completion in 2041-07-30. Interventions recorded: JNJ-90014496. Conditions listed: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05421663","url":"https://clinicaltrials.gov/study/NCT05421663"}],"tags":["ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["jnj-90014496"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05421663","phase":"1/2","setting":"A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma","sponsor":"Janssen Research & Development, LLC","enrolled":166,"outcomes":[]},"route":"/trials/nct05421663/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"jnj-90014496","kind":"drug","name":"JNJ-90014496","route":"/drugs/jnj-90014496/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}